...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity
【24h】

Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity

机译:新型苯并咪唑 - 丙烯腈杂交种及其衍生物:设计,合成和抗微生物活性

获取原文
获取原文并翻译 | 示例

摘要

This paper reports the synthesis and evaluation of some benzimidazole-acrylonitrile hybrid derivatives for their in vitro antimycobacterial activities against Mycobacterium tuberculosis H37Rv. Among the derivatives studied, 3b was found to be the most active compound with MIC of 0.78 mu g/mL against M. tuberculosis. This is a quite good activity compared with ethambutol (MIC = 1.56 mu g/mL). Moreover, 3b showed 2.8 log fold reduction in bacterial count of dormant forms of mycobacterium which is more potent than first line drugs isoniazid, ciprofloxacin, rifampicin and moxifloxacin. Having activities against both active and dormant forms of M. tuberculosis, 3b may be a useful candidate for the development of new drugs to treat tuberculosis. (C) 2019 Elsevier Masson SAS. All rights reserved.
机译:本文报道了一些苯并咪唑 - 丙烯腈杂交衍生物的合成和评价对其对分枝杆菌H37RV的体外抗微生物活性。 所研究的衍生物中,发现3b是具有0.78μg/ ml的MIC的最活性化合物,其针对结核分枝杆菌。 与乙胺醇(MIC =1.56μg/ ml)相比,这是一个相当良好的活动。 此外,3B显示了2.8点折叠的休眠形式的分枝杆菌的细菌数量,这比第一线药物异烟肼,环丙沙星,利福平和Moxifloxacin更有效。 在患有活跃和休眠形式的M.结核病的活动,3B可能是用于开发治疗结核病的新药的有用候选者。 (c)2019年Elsevier Masson SAS。 版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号